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Introduction {#cam41088-sec-0001}
============

Colorectal cancer (CRC) is the most common gastrointestinal cancer and one of the leading causes of cancer‐related deaths worldwide [1](#cam41088-bib-0001){ref-type="ref"}. At least two types of genomic instability are involved in CRC development, chromosomal instability, and microsatellite instability (MSI) [2](#cam41088-bib-0002){ref-type="ref"}. Microsatellite instability is an important biomarker to screen for Lynch syndrome (LS) [3](#cam41088-bib-0003){ref-type="ref"}. The consensus criteria for the diagnostic algorithm for LS are based on selecting patients who fulfill the Amsterdam criteria or any of the revised Bethesda guidelines (RBG), followed by MSI testing and/or immunohistochemistry (IHC) staining of MMR proteins [4](#cam41088-bib-0004){ref-type="ref"}. RBG is a set of clinical criteria that consist of age at CRC diagnosis, past history of cancers, family history of LS‐related cancers, and histopathological findings in CRC. Although the selection of patients by RBG is inexpensive and does not require technical expertise, relatively low sensitivity [5](#cam41088-bib-0005){ref-type="ref"} and have been shown to missing a substantial number of LS diagnosis. Therefore, universal tumor screening (UTS), which entails routine MSI (and/or IHC) testing for all CRCs, has been recommended in Western countries [6](#cam41088-bib-0006){ref-type="ref"}, [7](#cam41088-bib-0007){ref-type="ref"}. In fact, several studies have shown that UTS is cost effective [8](#cam41088-bib-0008){ref-type="ref"}, [9](#cam41088-bib-0009){ref-type="ref"}, [10](#cam41088-bib-0010){ref-type="ref"}. Implementing UTS in Asia including Japan is still controversial because the frequency of MSI‐H CRC is low (about 6% of CRCs) [11](#cam41088-bib-0011){ref-type="ref"}, [12](#cam41088-bib-0012){ref-type="ref"}, [13](#cam41088-bib-0013){ref-type="ref"} and the frequency of LS and the utility of RBG remain unknown.

Meanwhile, recent studies have demonstrated that microsatellite instability is also an important prognostic biomarker for CRC [14](#cam41088-bib-0014){ref-type="ref"} and may be useful as patient selection marker for adjuvant chemotherapy [15](#cam41088-bib-0015){ref-type="ref"}, [16](#cam41088-bib-0016){ref-type="ref"} and immune checkpoints inhibitors [17](#cam41088-bib-0017){ref-type="ref"}. Advanced CRC with MSI‐H demonstrated a high response rate to treatment with a programmed death‐1 (PD‐1) inhibitor, namely, an immune checkpoint inhibitor [17](#cam41088-bib-0017){ref-type="ref"}, and benefit of 5‐FU‐based adjuvant chemotherapy in patient with stage II or III MSI‐H CRC was not observed [18](#cam41088-bib-0018){ref-type="ref"}. Thus, MSI status is an important predictor of clinical benefit from these agents. This highlights why not only LS‐related CRC but also sporadic MSI‐H CRC should be identified. The majority of CRCs with MSI‐H are sporadic and develop as a result of silencing of *MLH1* by hypermethylation of its promoter [19](#cam41088-bib-0019){ref-type="ref"}, [20](#cam41088-bib-0020){ref-type="ref"}. All CRC cases less than 50 years of age are selected for MSI testing by RBG, but there are no criteria for CRC cases over 50 years of age to conduct MSI testing. Considering that most CRC patients are over 50 years of age and the fact that most of them are not MSI‐H, cost‐effective algorithm is required for elderly CRC patients.

To address this problem, we have developed a model to predict which CRC patients older than 50 years should undergo MSI testing on the basis of clinical and pathological data.

Materials and Methods {#cam41088-sec-0002}
=====================

Patients and samples {#cam41088-sec-0003}
--------------------

A total of 2387 consecutive patients with surgically resected CRC at the Saitama Cancer Center were enrolled in the test cohort from July 1999 to September 2014. A total of 1,648 consecutive patients with surgically resected CRC at Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, were enrolled in the validation cohort from January 2008 to August 2016. Patients with a history of preoperative radiotherapy or chemotherapy, inflammatory bowel disease, or a history of familial adenomatous polyposis were excluded. Clinical and pathological information was obtained from medical records.

Tumor tissues were resected surgically and stored at 4°C until time of sampling. A small piece of primary tumor and paired normal colorectal tissue was taken macroscopically by surgeons within 4 h after resection and stored at −80°C immediately. Histopathology was performed by pathologists using remnant tissues of sampling. Hematoxylin and eosin‐stained slides of tumor tissues were reviewed by pathologists to evaluate mucinous component. Tumors were considered mucinous component positive if more than 10% of their volume consisted of mucin, and were considered as mucinous adenocarcinoma if more than 50%.

Informed consent was obtained from all patients included in this study. The study was approved by the Ethics Committees of Saitama Cancer Center (No. 476) and Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital (No. 1433, No.1616). All procedures performed in this study were conducted in accordance with the ethical standards of Institutional and National Research Committees and with the 1964 Helsinki Declaration and its later amendments.

Analysis of *KRAS*/*RAF* mutation {#cam41088-sec-0004}
---------------------------------

Genomic DNA was extracted from fresh‐frozen tissue samples using the standard phenol--chloroform extraction method. *KRAS* mutations in exons 2, 3, and 4 were analyzed by high‐resolution melting analysis, using a Rotor‐Gene Q (Qiagen, Hilden, Germany) [11](#cam41088-bib-0011){ref-type="ref"}, [21](#cam41088-bib-0021){ref-type="ref"}, and *BRAF* mutations in exon 15 (codon 600) were detected by either polymerase chain reaction (PCR)‐restriction fragment length polymorphisms or high‐resolution melting analysis, as described previously [22](#cam41088-bib-0022){ref-type="ref"}.

Analysis of microsatellite instability {#cam41088-sec-0005}
--------------------------------------

MSI analysis was performed using fluorescence‐based PCR, as described previously [23](#cam41088-bib-0023){ref-type="ref"}. MSI status was determined using five Bethesda markers (BAT25, BAT26, D5S346, D2S123, and D17S250) and classified as MSI‐H (two or more markers demonstrated to be unstable), MSI‐low (MSI‐L; only one marker unstable), and MSS (no markers unstable). MSI‐positive markers were reexamined at least twice to confirm the results. MSI‐L was included with MSS in this study.

Analysis of *MLH1* promoter hypermethylation {#cam41088-sec-0006}
--------------------------------------------

All MSI‐H CRCs in the test cohort were analyzed for *MLH1* promoter methylation status by methylation‐specific PCR or combined bisulfite restriction analysis, as described previously [22](#cam41088-bib-0022){ref-type="ref"}.

Statistical analysis {#cam41088-sec-0007}
--------------------

Patient characteristics were compared using *t*‐tests for continuous variables and *χ* ^2^ or Fisher\'s exact tests for categorical variables. To select final predictors, all candidate predictors with a *P* \< 0.1 in univariate analysis were included in a multivariate logistic regression model. Scores for each predictor were obtained based on the beta value from the final prediction model. Final predictive scores were integers of standardized beta. A receiver‐operating characteristic (ROC) curve was drawn and the area under curve (AUC) was obtained [24](#cam41088-bib-0024){ref-type="ref"}. The dataset from Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital was analyzed for external validation. All analyses were carried out using SPSS software package version 22.0 (SPSS, Inc., IBM Corp., Armonk, NY).

Results {#cam41088-sec-0008}
=======

Patient characteristics {#cam41088-sec-0009}
-----------------------

Data were not available for 7 patients in the test cohort and 54 in the validation cohort. Data for 2380 patients in the test cohort and 1094 in the validation cohort were therefore included in the following analysis.

There were no significant differences in gender, *BRAF* mutation, and MSI status between the two cohorts. Mean age at diagnosis of CRC and location were significantly different, but were not clinically significant. Advanced stage, larger tumor size, mucinous component, and wild‐type *KRAS* were significantly more frequent in the validation cohort (Table [1](#cam41088-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline characteristics of test and validation cohorts

                            Test          Validation    *P*
  ------------------------- ------------- ------------- ---------
  Gender                                                
  Female                    988 (41.5)    473 (43.2)    0.339
  Male                      1392 (58.5)   621 (58.2)    
  Age at diagnosis of CRC                               
  Mean ± SD                 65.0 ± 10.2   66.3 ± 11.6   0.02
  Location                                              
  Proximal                  704 (29.6)    286 (26.1)    0.037
  Distal                    1676 (70.4)   808 (73.9)    
  Tumor size                                            
  Mean ± SD(mm)             45.6 ± 23.9   52.1 ± 23.9   \<0.001
  TNM stage                                             
  0--I                      532 (22.4)    124 (11.4)    \<0.001
  II                        745 (31.3)    374 (34.2)    
  III                       712 (29.9)    367 (33.5)    
  IV                        391 (16.4)    229 (20.9)    
  Mucinous component                                    
  −                         2086 (87.6)   902 (82.4)    \<0.001
  \+                        294 (12.4)    192 (17.6)    
  *KRAS*                                                
  Wild                      1370 (57.6)   784 (71.7)    \<0.001
  Mutant                    1010 (42.4)   310 (28.3)    
  *BRAF*                                                
  Wild                      2272 (95.5)   1042 (95.2)   0.778
  Mutant                    108 (4.5)     52 (4.8)      
  MSI status                                            
  MSI‐H                     139 (5.8)     60 (5.5)      0.675
  MSS                       2241 (94.2)   1034 (94.5)   

Proximal, cecum to transverse colon; Distal, splenic flexure to rectum; TNM, tumor node metastasis; MSI‐H, high‐frequency microsatellite instability; MSS, microsatellite stable.

John Wiley & Sons, Ltd

Univariate analysis in the test cohort {#cam41088-sec-0010}
--------------------------------------

There were 2219 patients aged ≥ 50 years in the test cohort and 992 in the validation cohort. The results of univariate analysis in the test cohort are shown in Table [2](#cam41088-tbl-0002){ref-type="table-wrap"}. CRCs with MSI‐H were more frequently associated with female sex (vs. MSS, *P *\<* *0.001), location in the proximal colon (vs. MSS, *P *\<* *0.001), large tumor size (vs. MSS, *P *\<* *0.001), mucinous component (vs. MSS, *P *\<* *0.001), and *BRAF* mutation (vs. MSS, *P *\<* *0.001), and were less frequently associated with *KRAS* mutation (vs. MSS, *P *=* *0.01). The mean age at CRC diagnosis was similar in patients with MSI‐H and MSS (*P *=* *0.07). Tumor size of MSI‐H CRCs was significantly larger than that of MSS CRCs in proximal (58.9 mm vs. 45.1 mm, *P *=* *0.001) and distal (56.8 mm vs. 44.4 mm, *P *=* *0.045). Thus, MSI‐H CRCs are larger than MSS CRCs regardless of tumor location.

###### 

Characteristics of CRC patients aged ≥50 years in relation to MSI

                            MSI‐H         MSS           *P*
  ------------------------- ------------- ------------- ---------
  Gender                                                
  Female                    70 (7.7)      841 (92.3)    \<0.001
  Male                      51 (3.9)      1257 (96.1)   
  Age at diagnosis of CRC                               
  Mean ± SD                 68.1 ± 9.56   66.4 ± 8.44   0.07
  Location                                              
  Proximal                  86 (12.9)     582 (87.1)    \<0.001
  Distal                    35 (2.3)      1516 (97.7)   
  Tumor size                                            
  Mean ± SD(mm)             58.3 ± 35.9   44.6 ± 22.5   \<0.001
  TNM stage                                             
  0‐I                       28 (5.6)      471 (94.4)    \<0.001
  62 (8.8)                  642 (91.2)                  
  21 (3.2)                  635 (96.8)                  
  10 (2.8)                  350 (97.2)                  
  Mucinous component                                    
  −                         79 (4.1)      1868 (95.9)   \<0.001
  \+                        42 (15.4)     230 (84.6)    
  *KRAS*                                                
  Wild                      82 (6.5)      1183 (93.5)   0.01
  Mutant                    39 (4.1)      915 (95.9)    
  *BRAF*                                                
  Wild                      75 (3.5)      2046 (96.5)   \<0.001
  Mutant                    46 (46.9)     52 (53.1)     

Proximal, cecum to transverse colon; Distal, splenic flexure to rectum; TNM, tumor node metastasis; MSI‐H, high‐frequency microsatellite instability; MSS, microsatellite stable.
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Multivariate analysis for predictive model {#cam41088-sec-0011}
------------------------------------------

According to multivariate analysis of tumor size, CRC with MSI‐H was more frequent in patients with tumors 0--19 mm (hazard ratio \[OR\] = 2.79, *P *=* *0.01, 95% confidence interval \[CI\]: 1.26--6.19), 20--29 mm (OR = 2.40, *P = *0.02, 95% CI: 1.15--5.02), and ≥ 60 mm (OR = 4.83, *P *\<* *0.001, 95% CI: 2.52--9.27), compared with the reference size (30--39 mm) (Table [3](#cam41088-tbl-0003){ref-type="table-wrap"}).

###### 

Multivariate analysis according to tumor size

                Beta   *P*    OR     95% CI   
  ------------- ------ ------ ------ -------- ------
  0--19 (mm)    1.03   0.01   2.79   1.26     6.19
  20--29 (mm)   0.88   0.02   2.40   1.15     5.02
  30--39 (mm)   ---    ---    Ref    ---      ---
  40--49 (mm)   0.35   0.38   1.42   0.64     3.13
  50--59 (mm)   0.28   0.52   1.32   0.57     3.09
  60‐ (mm)      1.58   0.00   4.83   2.52     9.27

John Wiley & Sons, Ltd

Multivariate logistic regression analysis was conducted including all of the above candidate predictors (gender, location, tumor size 0--19 mm, tumor size 20--29 mm, tumor size ≥ 60 mm, mucinous component, *KRAS* mutation, and *BRAF* mutation). *BRAF* mutation, female sex, mucinous component, location in proximal colon, and size ≥ 60 mm were subsequently selected as predictors based on a *P* \< 0.05. The final model of MSI predictors is shown in Table [4](#cam41088-tbl-0004){ref-type="table-wrap"}. Female sex scored 1 point, mucinous component and size ≥ 60 mm scored 2 points each, proximal location scored 3 points, and *BRAF* mutation scored 6 points. The sum of the scores for each patient was calculated and a ROC curve of the test cohort was constructed. The AUC of the prediction model was 0.832 (95% CI: 0.790--0.874). The sensitivity and specificity were 74.4% and 77.7%, respectively, for a cut‐off value of 4 points (Fig. [1](#cam41088-fig-0001){ref-type="fig"}A). The frequency of CRC with MSI‐H for each score is shown in Table [5](#cam41088-tbl-0005){ref-type="table-wrap"}. The frequencies of MSI‐H were 1.9% (0--3 points), 6.6% (4--5 points), and 30.6% (6--14 points) (Fig. [2](#cam41088-fig-0002){ref-type="fig"}). MSI‐H CRC with *MLH1* promoter hypermethylation was more frequent (59/70, 84.3%) in patients with a score ≥6, whereas MSI‐H CRC with unmethylated *MLH1* was more frequent (42/51, 82.4%) in those with a score ≤ 5 (*P *\<* *0.001) (Table [6](#cam41088-tbl-0006){ref-type="table-wrap"}). The AUC for *MLH1* promoter‐methylated CRC with MSI‐H was 0.901 (0.846--0.956) (Fig. [1](#cam41088-fig-0001){ref-type="fig"}B). Sixteen LS patients were included in this test cohort, and 93.3% (14/15) scored ≤ 5.

###### 

Multivariate analysis of factors predicting CRC with MSI‐H in patients aged ≥50 years

                  Beta   Odds    95% CI   Score   
  --------------- ------ ------- -------- ------- ---
  Female          0.44   1.56    1.02     2.38    1
  Size ≥ 60 mm    1.01   2.75    1.80     4.20    2
  Mucinous        0.76   2.13    1.32     3.42    2
  Proximal        1.32   3.76    2.41     5.86    3
  *BRAF* mutant   2.59   13.33   8.01     22.20   6

John Wiley & Sons, Ltd

![ROC curves of test and validation cohorts. (A) ROC curve of test cohort. (B) ROC curves of *MLH1* promoter methylation in the test cohort of CRC with MSI‐H. (C) ROC curve of validation cohort. ROC curves of test and validation cohorts were identical.](CAM4-6-1255-g001){#cam41088-fig-0001}

###### 

Frequency of CRC with MSI‐H among patients according to prediction score

  Score   MSI‐H/Total (%)   MSI‐H (*N* = 121)   Total (*N* = 2219)   MSI‐H (*N* = 121)   LS (*N* = 16)   
  ------- ----------------- ------------------- -------------------- ------------------- --------------- ---
  0       0.8               5                   657                  1                   4               1
  1       2.6               11                  424                  2                   9               4
  2       2.2               6                   276                  1                   5               1
  3       3.0               9                   305                  0                   9               1
  4       5.8               13                  224                  5                   8               4
  5       8.1               9                   111                  2                   7               4
  6       16.2              16                  99                   9                   7               0
  7       16.7              3                   18                   3                   0               0
  8       18.5              5                   27                   3                   2               1
  9       38.9              7                   18                   7                   0               0
  10      55.6              10                  18                   10                  0               0
  11      40.0              4                   10                   4                   0               0
  12      73.7              14                  19                   14                  0               0
  13      60.0%             3                   5                    3                   0               0
  14      75.0%             6                   8                    6                   0               0

*MLH1*‐M, *MLH1* promoter hypermethylated; un‐M, *MLH1* promoter unmethylated; LS, Lynch syndrome.

John Wiley & Sons, Ltd

![Frequency of CRC with MSI‐H. Frequency of CRC with MSI‐H according to prediction score in the test cohort. The frequency of CRC with MSI‐H increased with increasing score. ROC, receiver‐operating characteristic.](CAM4-6-1255-g002){#cam41088-fig-0002}

###### 

Presence of *MLH1* promoter hypermethylation in CRC with MSI‐H

                 *MLH1*‐M   un‐M   *P*
  -------------- ---------- ------ ---------
  0--5 points    11         42     \<0.001
  6--14 points   59         9      

Sensitivity = 84.3%, specificity = 82.4%.

*MLH1*‐M, *MLH1* promoter hypermethylated; un‐M, *MLH1* promoter unmethylated.

John Wiley & Sons, Ltd

Validation {#cam41088-sec-0012}
----------

We evaluated the accuracy of this model in an external validation cohort from Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital. The ROC curve of the validation cohort had an AUC of 0.856 (95% CI: 0.806--0.905). The sensitivity and specificity were 76.0% and 77.0%, respectively, for a cut‐off score of 4 points (Fig. [1](#cam41088-fig-0001){ref-type="fig"}C).

Discussion {#cam41088-sec-0013}
==========

In this study, we developed a model to predict MSI‐H CRC patients aged ≥ 50 years based on data from two CRC cohorts. The model demonstrated relatively high sensitivity and specificity, especially for sporadic CRC with MSI‐H, and was robust according to external validation.

According to this model, 30.6% of CRC patients with a prediction score ≥ 6 had MSI‐H, whereas 98.1% (1631/1662) with a score ≤ 3 had MSS. This model could thus reduce the time and cost involved in identifying MSI‐H CRC. The results suggest that MSI testing should be strongly recommended in patients with a score ≥ 6, should ideally be carried out in those with a score of 4 or 5, and if possible, in those with a score ≤ 3. Furthermore, *MLH1* promoter‐hypermethylated CRCs were more frequent among patients with a score ≥ 6, whereas unmethylated ones, including LS‐related CRCs, were more frequent in those with a score ≤ 5. This model could therefore also anticipate the presence of *MLH1* promoter hypermethylation after MSI testing.

MSI status is an important biomarker for prognosis, and potential patient selection biomarker for adjuvant chemotherapy and immune checkpoints inhibitor. Frequency of MSI‐H is very low in stage III and IV CRCs, 3.2% and 2.8%, respectively (Table [2](#cam41088-tbl-0002){ref-type="table-wrap"}). Therefore, appropriate selection from stage III and IV CRCs is required for cost effectiveness. Among stage III and IV CRCs (*N* = 1016), frequency of MSI‐H that scored 0--3 points is 0.95% (7/740), scored 4--5 points is 3.2% (5/155), and scored 6 points or more is 15.7% (19/121), and is enriched about fivefold in ≥6 points group. That is, 61.3% (19/31) of CRCs with MSI‐H is included in ≥6 points group. Thus, this enrichment will help decision making of MSI testing.

Several predictive models have previously been reported [25](#cam41088-bib-0025){ref-type="ref"}, [26](#cam41088-bib-0026){ref-type="ref"}, [27](#cam41088-bib-0027){ref-type="ref"}, including pathological findings such as Crohn‐like reaction, tumor‐infiltrating lymphocytes, cribriform, Ki67 index, and p53 overexpression. These predictive models may be highly sensitive and specific, but the requirement for detailed pathological diagnosis puts a big burden on the pathologists.

The current predictive model identified five predictors by multivariate logistic regression analysis: *BRAF* mutation, female sex, location in the proximal colon, and tumor size ≥ 60 mm; will be available as a result of routine medical treatment. Information on mucinous component will also be available if a pathologist helps to evaluate this. This is the first predictive model to include *BRAF* mutation as a predictive factor. *BRAF* mutation analysis is currently not so common in CRC patients, but multigene testing including *KRAS*,*NRAS*, and *BRAF* by luminex‐based multiplex assay will be available soon in Japan, and the European Society for Medical Oncology consensus guidelines recommend *BRAF* testing as grade B [28](#cam41088-bib-0028){ref-type="ref"}. In addition, multigene testing by Next‐Generation Sequencing will become increasingly utilized in many countries to select appropriate cancer therapy [29](#cam41088-bib-0029){ref-type="ref"}. *BRAF* mutation is significantly associated with MSI‐H, especially MSI‐H with *MLH1* promoter hypermethylation [20](#cam41088-bib-0020){ref-type="ref"}, [30](#cam41088-bib-0030){ref-type="ref"}, [31](#cam41088-bib-0031){ref-type="ref"}, [32](#cam41088-bib-0032){ref-type="ref"}. *BRAF* mutation was the strongest predictor in our model, suggesting that this model could select more CRCs with hypermethylated, compared with CRCs with unmethylated *MLH1* promoters. The incidence of MSI‐H CRCs is known to be increased in older women, in tumors located in the proximal colon, and among mucinous component tumors [33](#cam41088-bib-0033){ref-type="ref"}. CRC with *MLH1* promoter hypermethylation is also more common in women [19](#cam41088-bib-0019){ref-type="ref"}. The frequency of *BRAF* mutations varies widely from 1.1% to 15.3% worldwide [29](#cam41088-bib-0029){ref-type="ref"}, [34](#cam41088-bib-0034){ref-type="ref"}, [35](#cam41088-bib-0035){ref-type="ref"}, [36](#cam41088-bib-0036){ref-type="ref"}, [37](#cam41088-bib-0037){ref-type="ref"}, [38](#cam41088-bib-0038){ref-type="ref"}. The *BRAF* V600E mutation frequency of 4.5--4.8% observed in this study is consistent with various Asian studies (1.1% to 4.9%), but is slightly lower than several Western studies (7.0--15.3%). In contrast, it has recently been reported that *BRAF* non‐V600E mutations were found more frequently in Asian than in Western [39](#cam41088-bib-0039){ref-type="ref"}, [40](#cam41088-bib-0040){ref-type="ref"}, [41](#cam41088-bib-0041){ref-type="ref"}. However, it remains unknown whether *BRAF* non‐V600E mutations correlate with MSI‐H CRC or not.

Similar to our predictive model, Hyde et al. also included proximal location and mucinous component [26](#cam41088-bib-0026){ref-type="ref"}, and Colomer et al. included mucinous component and tumor size in their models [27](#cam41088-bib-0027){ref-type="ref"}. Considering tumor size, CRCs with MSI‐H are known to be larger than CRCs with MSS [14](#cam41088-bib-0014){ref-type="ref"}, [31](#cam41088-bib-0031){ref-type="ref"}. Our data also showed significant difference between MSI‐H and MSS, regardless of tumor location. We used a cut‐off value for tumor size of ≥60 mm, compared with \> 65 mm in Colomer et al. model [27](#cam41088-bib-0027){ref-type="ref"} and \> 50 mm in Batur et al. report [42](#cam41088-bib-0042){ref-type="ref"}. It is difficult to judge the optimal cut‐off for tumor size as a predictor because tumor size changes according to the stage or timing of operation. However, typical CRCs do not grow to ≥60 mm [43](#cam41088-bib-0043){ref-type="ref"}, [44](#cam41088-bib-0044){ref-type="ref"}, and the cut‐off values were therefore appropriate based on the characteristic large size of CRCs with MSI‐H. It is interesting to note that the frequency of MSI‐H CRC is higher in the group of tumors that are smaller in size (Table [3](#cam41088-tbl-0003){ref-type="table-wrap"}). One of the reasons for this may be that the high‐risk group, such as LS or suspected LS cases, had taken regular colonoscopic surveillance. This may lead to diagnosis of CRC at an earlier stage. Further investigations are required to clarify this observation.

Regarding LS, 25 patients with LS‐related CRCs were enrolled across all ages in the test cohort, including 16 (64%) among patients ≥ 50 years, of whom 43% (7/16) scored ≤ 3.

CRC patients with MSI‐H could not be perfectly isolated in the test cohort. Thirty‐one CRCs with MSI‐H were included among 1662 cases that scored ≤ 3, accounting for 25.6% (31/121) of all CRCs with MSI‐H. Among 1886 CRCs with *BRAF* wild‐type and no mucinous component, 51 (2.7%) CRC were MSI‐H, 31 cases scored 0--3 points, 10 cases scored 4--5 points, and 10 cases scored ≥ 6 points. The current predictive model could identify 39.2% (20/51) of MSI‐H CRC with *BRAF* wild‐type and no mucinous component. Inamura et al. reported that the existence of signet‐ring cell component is associated with MSI‐H [45](#cam41088-bib-0045){ref-type="ref"}. If our prediction model incorporates signet‐ring cell component, prediction rate may be improved.

There were some limitations to this study. Tissue samples were not assessed for quality microscopically to evaluate presence of cancer cells.

In conclusion, we developed a predictive model to determine the need for MSI testing among CRC patients aged ≥ 50 years. This model can help to identify those CRCs with MSI‐H, especially sporadic CRC with MSI‐H.

We expect that this predictive model will be useful in clinical situations, such as determining which patients should be recommended for indication for 5‐fluorouracil‐based adjuvant therapy and to identify those patients who may derive therapeutic benefit from immune checkpoint inhibitors.
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